Jonathan Adly
- Founder & CEO at TJM Labs
GetLatka interview
How TJM Labs Reached $25M ARR and 450 Pharmacies with 40% EBITDA (Interview with Jonathan Adly)
Jonathan Adly (Founder & CEO of TJM Labs) spoke to Nathan Latka on July 7, 2026.
TJM Labs figures from the interview
- ARR (2026)
- $25M
- EBITDA Margin (2026)
- 40%
- Pharmacy Customers (2026)
- 450
- Avg Contract Value (2026)
- $45,000 per bot per year
- Total Funding Raised
- $100M
“Yeah, I mean, I can share my revenue, my revenue is about, it's close to 25,000,000 ARR, right? That's not a secret.”
“Everybody in that period was thinking like, I want to be the system of record for this specific slice of industry. And that would be the win. Versus I was like, I don't care about being the system of record. I want to be the system of action.”
“Yeah, so our average ACV is about $45K a year, right? And if you know what it is, that is slightly less than the salary of a pharmacy technician, and that's how we price it. You can hire a digital worker for 45 k a year, or you can hire three human worker, and that will cost you 150 k a year, right, or more if you count benefits and payroll and all of that stuff.”
Bio
Jonathan Adly is the founder and CEO of TJM Labs, a pharmacy AI platform headquartered in the United States. Adly grew up in a family that pushed him toward medicine, and pharmacy became a compromise between his parents' wishes and his own ambitions. He earned a PharmD, completed a postdoctoral residency, and later pursued an MBA as he transitioned toward entrepreneurship. His early career included academic publishing and administrative roles within health systems, where he developed a deep understanding of pharmacy supply chains and government interventions affecting pharmacy economics. Before founding TJM Labs, Adly founded Galen AI, a B2B healthcare AI company built on a software stack similar to Open Evidence. Galen AI was bootstrapped, signed its first enterprise customer at a contract value in the range of $250,000 to over $1 million per year, and was acquired within approximately a year and a half of founding. The acquirer was Carrie RX, which Adly described as a great software company that valued Galen AI's early AI infrastructure. Adly then joined Carrie RX as head of AI infrastructure. Carrie RX itself was subsequently acquired approximately six months before the July 2026 interview. Adly described the Galen AI exit as a meaningful personal financial event, though specific revenue figures are under NDA. Adly founded TJM Labs in late 2024, writing the first line of code in November 2024 after a pharmacy customer needed to rapidly staff approximately 200 technicians in four weeks. The company officially launched to additional customers in February 2025 with $1 million in ARR, scaled to $15 million ARR by December 2025, and reached approximately $25 million ARR by mid-2026, serving 450 pharmacy logos. TJM Labs raised a $10 million Series A in December 2025, a $15 million Series A1 in March 2026, and a $75 million Series B from Elephant in June 2026 at greater than 15x ARR multiple, implying a valuation above $375 million. The company operates at 40% EBITDA margin and its bots process roughly 500,000 prescriptions per day.